Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:51:23.948Z.
Calculation as of: 2026-10-06T14:51:23.948Z.
Quote observation: 2026-10-06T14:50:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f13a1340446ed9d2fab2f71bf594eb69a7c02e94fe434461414907d992f5ed7
PEG RATIO
N/A
Market Cap
$1.02B
PEG Ratio
N/A
TTM Avg
13.10
3Y Avg
5.81
5Y Avg
15.85
Market Cap
$1.02B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$982.03M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $1.02B | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | N/A | 13.10 | 5.81 | 15.85 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $998.42M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.34M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $986.27M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.03M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
